Edgar Filing: Wolchko J Scott - Form 4

Wolchko J S Form 4	Scott										
April 19, 20											
FORM	A 4 UNITED	STATES		RITIES AND EXCHANGE COMMIS					OMB APPROVAL OMB 3235-028		
Check t	his box		Wa	shington	, D.C. 2	0549			Number:	January 31,	
if no lor subject Section Form 4	F CHANGES IN BENEFICIAL OWNERSHI SECURITIES						Expires: Estimated a burden hour response	2005 verage			
Form 5 obligation may con <i>See</i> Inst 1(b).	ons ntinue. Section 17((a) of the P	ublic U	tility Hol	ding Co	mpar	•	Act of 1934, 935 or Section	l		
(Print or Type	Responses)										
Wolchko J Scott Symi FAT				THERAPEUTICS INC				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last)		[FATE] 3. Date of Earliest Transaction					X_ Director 10% Owner				
C/O FATE	THERAPEUTIC 5 GENERAL AT	S,		Day/Year)	Tansaction		-	_XOfficer (give below)			
	(Street)			endment, D onth/Day/Yea	-	al	-	5. Individual or Joi Applicable Line) X_ Form filed by O Form filed by M	ne Reporting Pe	rson	
	GO, CA 92121	(7 in)					F	Person			
(City)	(State)	(Zip)						red, Disposed of,		-	
1.Title of Security (Instr. 3)		saction Date 2A. Deemed 3 /Day/Year) Execution Date, if 7 any (Month/Day/Year) (sed of 4 and (A) or	(D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Common Stock	04/17/2019			M <u>(1)</u>	1,092	A	\$ 1.63	375,973	D		
Common Stock	04/17/2019			S <u>(1)</u>	1,092	D	\$ 16.1062 (2)	374,881	D		
Common Stock	04/17/2019			M <u>(1)</u>	7,449	А	\$ 1.63	382,330	D		
Common Stock	04/17/2019			S <u>(1)</u>	7,449	D	\$ 16.1826	374,881	D		

Edgar Filing: Wolchko J Scott - Form 4

					(3)		
Common Stock	04/18/2019	M <u>(1)</u>	6,843	А	\$ 1.63	381,724	D
Common Stock	04/18/2019	S <u>(1)</u>	6,843	D	\$ 16.014 (4)	374,881	D
Common Stock	04/18/2019	M <u>(1)</u>	4,616	А	\$ 1.63	379,497	D
Common Stock	04/18/2019	S <u>(1)</u>	4,616	D	\$ 16.015 (4)	374,881	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02) required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number prof Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. l De Sec (In
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (right to buy)	\$ 1.63	04/17/2019		M <u>(1)</u>	1,092	(5)	02/08/2022	Common Stock	1,092	
Stock Option (right to buy)	\$ 1.63	04/17/2019		M <u>(1)</u>	7,449	(7)	02/08/2022	Common Stock	7,449	
Stock Option (right to buy)	\$ 1.63	04/18/2019		M <u>(1)</u>	6,843	(5)	02/08/2022	Common Stock	6,843	
Stock Option (right to	\$ 1.63	04/18/2019		M <u>(1)</u>	4,616	(7)	02/08/2022	Common Stock	4,616	

buy)

Reporting Owners

Reporting Owner Name / Address		Relationships						
	Director	10% Owner	Officer	Other				
Wolchko J Scott C/O FATE THERAPEUTICS, INC.; 3535 GENERAL ATOMICS COURT #200 SAN DIEGO, CA 92121	Х		President and CEO					
Signatures								
/s/ Cindy R. Tahl, as Attorney-in-Fact	04/19/2019)						
** Signature of Reporting Person	Date							

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 20, 2018.

Represents the weighted average sale price of the shares sold ranging from \$16.00 to \$16.73 per share. The Reporting Person will(2) provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price.

Represents the weighted average sale price of the shares sold ranging from \$16.00 to \$16.84 per share. The Reporting person will(3) provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price.

Represents the weighted average sale price of the shares sold ranging from \$16.00 to \$16.04 per share. The Reporting person will(4) provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price.

- (5) The shares subject to this option became fully vested and exercisable on May 30, 2015.
- (6) Not applicable.
- (7) The shares subject to this option became fully vested and exercisable on October 4, 2015.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.